A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial

Abstract

The long-term outcome of SCLC was not improved by raising the dose intensity of ICE chemotherapy by threefold.

Complexity and health – yesterday's traditions, tomorrow's future

“…In this context, we wholeheartedly agree with Isabelle Stengers [25] who emphasized emphatically that the discovery and study of surprising phenomena -like the observation that more intensive glucose control increases mortality [26] or increasing the dose of chemotherapy not improving therapeutic response or survival [27] or the large investment in health services not being matched by a similar magnitude of improvement in inequity between social classes [28] -should not result in a rupture inside the medical sciences, but rather create the opportunity to entertain a different relationship with our past approaches -highlighting 'openness, surprise, the demand of relevance, the creative aspect of the scientific adventure, and not reduction to simplicity. ' The intellectual challenges that researchers experience in medicine and health services at the beginning of the 21st century are no different to those experienced by researchers like Gallileo and [26] response to coumadin-therapy increasing the dose of chemotherapy does not improve therapeutic response or survival [27] chemotherapy initially reduces tumour size but also includes the promotion of secondary tumours [34] large investment in health services has not been matched by a similar magnitude of improvement in inequity between social classes [28] the introduction of electronic prescribing systems had mixed impacts on appropriateness and safety of prescribing and patient health outcomes [35,36] Open to environment…”

“…' The intellectual challenges that researchers experience in medicine and health services at the beginning of the 21st century are no different to those experienced by researchers like Gallileo and [26] response to coumadin-therapy increasing the dose of chemotherapy does not improve therapeutic response or survival [27] chemotherapy initially reduces tumour size but also includes the promotion of secondary tumours [34] large investment in health services has not been matched by a similar magnitude of improvement in inequity between social classes [28] the introduction of electronic prescribing systems had mixed impacts on appropriateness and safety of prescribing and patient health outcomes [35,36] Open to environment…”

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

“…No difference in the median progression-free survival and OS was noted among the two arms. 67 Some limitations of the study may have accounted for the lack of favourable results.…”

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

“…A meta-analysis on this topic concluded that there is no place for the routine use of haematological colony-stimulating factors in the treatment of SCLC for the purpose of increasing dose intensity [48], although there is a role for growth factors for the prevention of infection. Two phase III trials, including both patients with LS-and with ES-SCLC, demonstrated increased haematological toxicity but no improved survival when combining myeloablative chemotherapy with autologous haematopoietic stem cell reinfusion [49,50].…”